

Stockholm, March 12, 2013

Information regarding the inaccurate disclosure in Biotage/Active Biotech

On March 11, Investor formally disclosed the purchase of shares in Active Biotech, as previously announced on March 6. The disclosure was carried out by law firm Roschier. Of yet to be determined reasons, the disclosure which was sent out at 13:42 pm, was wrongly headlined as Biotage. The ISIN-code, describing which stock the disclosure refers to was correct (Active Biotech), however the company name was incorrect. The FSA (Finansinspektionen) sent out a correction at 13:53 pm where the company name had been corrected to Active Biotech. We are currently, together with Roschier, investigating how this error could occur and we have requested further information from the FSA regarding this matter. Until this issue has been resolved, we will handle all disclosures manually.

During the eleven minutes that elapsed between the disclosure with the false company name and the disclosure with the correct company name, the share price in Biotage rose about 10 percent. The share price fell back again after the correct disclosure.

NASDAQ OMX Stockholm is, according to standard procedure investigating the matter, and all trades made in Biotage at the elevated share price during the time the incorrect information was available have been cancelled.

Investor Growth Capital, a wholly owned but standalone unit from Investor, holds shares in Biotage since 2003. Biotage shares have been sold through Investor's trading unit during one week early in 2013, as well as during the past week. In total, 50,000 shares were divested in Biotage during March 11 in the SEK 9.15-9.25 price range, of which the majority was divested prior to the incorrect disclosure. Investor Growth Capital did not divest any shares at the elevated price levels.